Today, CLC bio is pleased to announce that the positive growth rates of recent years have continued in 2011 with a 30% increase in software sales and a growth in operating profit of more than 50% compared to 2010.
“We're still a positive cash flow company and have increased our annual profits by more than 50% to more than 1 million USD - a significant factor in our continued investment in product development and expanded market reach.”
"Despite 2011 being the first year where we experienced our customers being impacted by the financial crisis in Europe and the US, we still managed to achieve a 30% increase in software sales, compared to 2010. Furthermore, we had a 52% increase in the number of organizations owning licenses for our software, rising to above 1500 in total." states CEO at CLC bio, Thomas Knudsen, and continues, "We're still a positive cash flow company and have increased our annual profits by more than 50% to more than 1 million USD - a significant factor in our continued investment in product development and expanded market reach."
Director of Communications at CLC bio, Lasse Görlitz, adds, "Our growth is evidenced throughout the company, with the number of employees increasing in 2011 by 34%. Looking behind the overall sales figures we're extremely pleased to see a doubling in installations of our enterprise platform, as well as helping our third-party collaborators starting to generate revenue through our open platform - an area we anticipate will grow substantially in 2012!"
Can brain-healthy eating improve your quality of life? This study tested it